Introduction
============

Chronic obstructive pulmonary disease is a major and increasing cause of disability in our aging population. Progressive damage to lung tissue is associated with increased shortness of breath on exertion leading to a "vicious cycle" of inactivity and worsening shortness of breath. While impaired lung mechanics is clearly the primary cause of disability in COPD patients, symptoms of leg fatigue are just as likely as breathlessness to cause these individuals to stop exercising ([@b12-copd-1-73]). Exercise intolerance has been associated with changes in the peripheral muscle of patients with COPD. Prolonged physical inactivity and pathological dysfunction in the skeletal muscle of COPD patients are thought to decrease muscle mass and capillary density, alter muscle fiber-type distribution, lower the activity of oxidative enzymes, and increase glycolytic enzyme activity (for a review, see [@b4-copd-1-73]). Although these morphological and biochemical changes contribute to exercise intolerance in patients with COPD, several studies indicate (and O~2~ utilization) per se may not be the primary factor that muscle metabolism limiting exercise capacity ([@b28-copd-1-73]; [@b19-copd-1-73]). Therefore, it is also possible that exercise capacity in COPD patients is limited by factors mediating muscle blood flow and O~2~ delivery to the active muscle.

The impact of COPD on blood flow and O~2~ delivery to the exercising muscle is not well understood. While there is some evidence to suggest that leg blood flow may not be limited at rest and during submaximal exercise in COPD patients ([@b17-copd-1-73]), [@b31-copd-1-73] have reported a plateau in lower limb blood flow during incremental exercise in some individuals with severe COPD. The inability to increase leg blood flow and O~2~ delivery in line with a rising metabolic rate may contribute to muscle fatigue and adversely affect exercise tolerance. One factor that could limit limb blood flow during exercise is a loss of vasodilatory capacity (as measured by peak blood flow or conductance following reactive hyperemia). [@b5-copd-1-73] reported that peak hyperemic calf blood flow (CBF) was not significantly different in patients with moderate-to-severe COPD when compared with control subjects. However, peak CBF in this study tended to be twice as high in the COPD patients as in the control subjects. Peak CBF in the control group was, in turn, approximately three times lower than previously published values ([@b14-copd-1-73]). Thus, while COPD patients with even mild-to-moderate levels of disease show a loss of exercise capacity, it is unclear what the effect of COPD (and associated physical inactivity) is on skeletal muscle vasodilatory capacity.

In healthy older individuals, maximal or peak CBF and peak conductance are significantly correlated with peak exercise capacity (peak O~2~ uptake; V̇O~2peak~), leading some researchers to suggest that the ability to regulate blood flow may be a limiting factor to exercise capacity in these individuals ([@b32-copd-1-73]; [@b22-copd-1-73]). Vasodilatory capacity has also been shown to increase with endurance training in young and older individuals ([@b21-copd-1-73], [@b22-copd-1-73]). These studies demonstrate that an increase in physical activity could improve limb vasodilatory capacity. Based on the evidence presented, it may be that a reduction in V̇O~2peak~, secondary to a decline in physical activity, is accompanied by a loss in the maximum ability of the peripheral vasculature to increase muscle blood flow in patients with COPD.

To date, no study has examined the relationship between exercise capacity and lower limb CBF and conductance in patients with moderate COPD. The aim of this study was to compare exercise capacity and peak CBF responses in patients with moderate COPD. We hypothesized that patients with moderate COPD would have a lower V̇O~2peak~, peak CBF, and peak calf conductance than age-matched healthy subjects.

Methods
=======

Subjects
--------

Eighteen male subjects aged between 60 and 80 years volunteered to participate in this study: nine individuals with moderate COPD and nine healthy age-matched controls. Inclusion criteria for the COPD patients were moderate expiratory flow limitation as evidenced by FEV~1~ between 80% and 30% of predicted values ([@b25-copd-1-73]), shortness of breath on exertion, and no documented history of substantial comorbidity. Diagnosis of COPD was based on a medical history questionnaire and pulmonary function test results. The control subjects were healthy non-smokers with no current or past history of cardiopulmonary disorders. Subjects were excluded from the study if they were taking vasoactive medications that may have affected blood flow.

Experimental design
-------------------

All testing was performed in the Physiology of Exercise Research Laboratory, Gold Coast campus, Griffith University, QLD, Australia. Subjects visited the laboratory on three separate occasions. During the first visit, they underwent preliminary health screening and were familiarized with the methods to be used in the study. On the second visit, an incremental exercise test was performed on a cycle ergometer. The third and final visit involved the measurement of CBF, calf volume, and percentage body fat. The study was approved by the Griffith University Human Research Ethics Committee and all subjects provided written informed consent prior to their participation.

Pulmonary function and anthropometry
------------------------------------

Pulmonary function was measured and assessed using standard techniques ([@b1-copd-1-73]). FVC, FEV~1~, residual volume (RV), and diffusion capacity for carbon monoxide (DL~CO~) were measured using a Collins GS Modular Pulmonary Function Testing system (Braintree, MA, USA). Maximal voluntary ventilation (MVV) was estimated as FEV~1~× 35 ([@b23-copd-1-73]). Disease severity was classified in accordance with The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines ([@b25-copd-1-73]).

To estimate percentage body fat, skinfold thickness was measured using a Harpenden skinfold caliper (Baty International, West Sussex, UK) at four sites on the upper body: biceps, triceps, subscapular, and suprailiac ([@b7-copd-1-73]). To obtain an estimate of leg adiposity, skinfold thickness of the anterior thigh and medial calf of the right leg was measured (ie, the leg in which blood flow and calf volume were determined). Calf volume was measured using a geometric method as described by [@b11-copd-1-73].

Incremental exercise test
-------------------------

The incremental exercise test used to measure V̇O~2peak~ was performed on a Lode cycle ergometer (Excalibur Sport, Groningen, The Netherlands). Subjects began unloaded cycling for 3 minutes and then the power output was increased by 8 W·min^−1^ for the COPD group and by 15 W·min^−1^ for the healthy control group. Subjects were encouraged to maintain a pedal cadence of 60--70 rev·min^−1^ until volitional termination of the test.

Throughout the incremental cycling test, O~2~ uptake (V̇O~2~) and expired ventilation (V̇~E~) were measured breath-by-breath and averaged over 30-second intervals using a metabolic measuring system (MedGraphics CPX/D, St Paul, MN, USA). A 12-lead ECG was used to monitor cardiac rhythm and to determine heart rate. Peak exercise values for incremental cycling were calculated as the average of the two highest consecutive 30-second values obtained before termination of exercise. A medical practitioner supervised each incremental exercise test.

Calf blood flow and conductance
-------------------------------

CBF was measured using venous occlusion plethysmography ([@b35-copd-1-73]). All blood flow tests were conducted at the same time in the morning in a quiet room with a constant ambient temperature between 23 and 24°C. Subjects fasted for 3 hours before the test and did not consume any caffeine or alcohol during the morning of the test. Additionally, all subjects refrained from strenuous exercise for 24 hours before the test.

Prior to the blood flow measurements, the subject was instructed to lie supine on a bed for 30 minutes. The right leg was elevated to the level of the heart by supporting the lower part of the leg (18 cm above and parallel to the bed) using a foam block under the knee and a strap supporting the foot. A 22-cm contoured thigh cuff was placed around the lower part of the thigh, just above the knee, and connected to a Rapid Cuff Inflator (Hokanson E20, Bellevue, WA, USA). The foot was isolated from the circulation by a 5-cm cuff positioned around the ankle and inflated to 240 mmHg. A mercury-in-rubber strain gauge was placed around the calf at the point of greatest girth. The strain gauge was interfaced to a computer via a Biopac Data Acquisition System (AcqKnowledge software, Biopac Systems Inc, CA, USA). The signal from the strain gauge was sampled at 100 Hz and filtered using a Hanning 3-Hz low-pass filter.

Baseline CBF was recorded in two trials of 3 minutes' duration. During each trial, the thigh cuff was intermittently inflated to 60 mmHg (thereby permitting arterial inflow of blood but occluding venous outflow), in a duty cycle of 30 seconds (15 seconds on and 15 seconds off). CBF was then determined by measuring the increase in calf circumference (ie, the initial slope of the signal recorded from the strain gauge) immediately after the cuff was inflated ([@b30-copd-1-73]). To avoid movement artifact, the first second of the signal immediately after the cuff was inflated was excluded from the analysis. The initial slope was then determined from the following 3 seconds of data ([Figure 1a](#f1-copd-1-73){ref-type="fig"}). The mean value of at least six serial blood flow measurements was determined as baseline CBF per trial in milliliters per 100 mL calf volume per minute.

Peak CBF was determined after two successive 5-minute periods of arterial occlusion, which were induced by inflating the thigh cuff to a pressure of 220 mmHg ([@b6-copd-1-73]). A resting period of 15 minutes was permitted between the two successive ischemic periods to ensure blood flow had returned to baseline ([@b30-copd-1-73]; [@b27-copd-1-73]). Immediately after the 5-minute period of arterial occlusion, 12 serial blood flow measurements were recorded over a period of 3 minutes by intermittently inflating the thigh cuff to a pressure of 80 mmHg ([@b20-copd-1-73]). To monitor reactive hyperemic blood flow over time, a duty cycle of 15 seconds was used (8 on, 7 off), as previously described ([@b6-copd-1-73]). The first blood flow measurement began 7 seconds after the end of the arterial occlusion period, and peak CBF was accepted as the highest flow obtained during the successive measurements. All peak CBF measurements are also presented as a multiple of baseline CBF. In our laboratory, the day-to-day test-retest reliability (intra-class correlation coefficient) for measuring resting and peak CBF was 0.95 and 0.96, respectively (n=10).

From each subject's blood flow versus time curve ([Figure 1b](#f1-copd-1-73){ref-type="fig"}), the rate of decay in CBF (the slopes of the logarithmic function of blood flow versus time, illustrated in [Figure 1c](#f1-copd-1-73){ref-type="fig"}) was determined ([@b9-copd-1-73]). Excess blood flow was determined by calculating the area under the blood flow versus time curve minus baseline CBF for the duration of the 3-minute post-ischemic measurement period.

During the measurement of baseline and post-ischemic CBF, heart rate and systolic and diastolic blood pressure were recorded using a Finapres (Ohmeda 2300 Finapres, Engelwood, CO, USA). The calculated mean arterial pressure (MAP) signal from the Finapres was recorded simultaneously with the strain gauge signal from the plethysmograph using the data acquisition software. Baseline and peak calf conductance were calculated from CBF and MAP:
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Statistical analysis
--------------------

All results are presented as group means ± SD. Differences between groups in the dependent variables were determined using independent-sample *t* tests. The time-course change in hyperemic CBF was assessed using a 2-way repeated measures ANOVA (analysis of variance) with Bonferroni post hoc adjustments. Pearson's product-moment correlation coefficients were calculated to assess the relationships between blood flow measurements and V̇O~2peak~. Statistical significance was accepted at p \< 0.05.

Results
=======

The physical characteristics of the subjects are presented in [Table 1](#t1-copd-1-73){ref-type="table"}. The groups were well matched with respect to their physical characteristics. There were no significant differences between the groups in age, height, weight, blood pressure, calf volume, percentage body fat, or sum of the leg skinfolds.

Pulmonary function test results for the two groups are presented in [Table 2](#t2-copd-1-73){ref-type="table"}. Patients with COPD had significantly lower FVC, FEV~1~, FEV~1~/FVC, MVV, and DL~CO~ values than the control group. RV was significantly greater in the COPD group. All lung function values for the control subjects were within the range of predicted values for healthy individuals of that age group ([@b13-copd-1-73]).

The results of the incremental exercise test are provided in [Table 3](#t3-copd-1-73){ref-type="table"}. V̇O~2peak~ was significantly lower in the COPD group. The average peak power output achieved in the COPD group was only 42.8% of the peak power attained by the control group. Peak exercise heart rate was also significantly lower in the COPD group. The control subjects reached 100.5% of their age-predicted maximum heart rate, whereas the patients with COPD reached only 79.8% of their predicted maximum. Peak exercise ventilation (V̇~Epeak~), respiratory exchange ratio, and power output values were all significantly lower in the COPD group. However, when V̇~Epeak~ was expressed as a percentage of MVV, no significant difference was found between the two groups (p=0.84). The COPD group reached 84.1% of their estimated MVV, while the control group reached 85.9%. During the incremental cycling test, all subjects in the control group stopped exercise because of leg fatigue. In the COPD group, four subjects stopped exercise because of leg fatigue, two because of shortness of breath, and three from a combination of leg fatigue and breathlessness.

There were no significant differences between the two groups in resting (p=0.83) or peak CBF (p=0.85) ([Figure 2a](#f2-copd-1-73){ref-type="fig"}). The resting (COPD 3.8 ± 1.0 mL·100 mL^−1^·min^−1^; control 3.7 ± 1.4 mL·100 mL^−1^·min^−1^) and peak (COPD 24.7 ± 6.5 mL·100 mL^−1^·min^−1^; control25.5 ± 9.1 mL·100 mL^−1^·min^−1^) CBF results in our study were similar to those reported in other studies that used similar methods of determining CBF in older individuals ([@b14-copd-1-73], [@b15-copd-1-73]). Baseline and peak calf conductance were also not significantly different between the COPD patients and healthy control subjects ([Figure 2b](#f2-copd-1-73){ref-type="fig"}). There were no significant differences between the groups in peak CBF expressed as a function of resting CBF (peak CBF/baseline CBF) (COPD 6.8 ± 1.8, control 7.3 ± 2.4; p=0.63). Similarly, the comparison of peak conductance as a function of resting conductance (peak conductance/baseline conductance) was not significantly different between the groups (COPD 6.8 ± 1.9, control 7.6 ± 2.7; p=0.44). [Figure 1b](#f1-copd-1-73){ref-type="fig"} illustrates the time-course changes in CBF in both groups. CBF attained its peak value at the first measurement point, 7 seconds after cuff release, and then decreased significantly in both groups during the first 90 seconds of the 3-minute measurement period. Thereafter, CBF returned to baseline values, with no further decrease observed in either group. Although there were no significant differences in CBF between the groups at any measurement period, the rate of decay in CBF was significantly slower in the COPD group (−0.036 ± 0.005 mL·100 mL^−1^·min^−1^·s^−1^) than in the control group (−0.048 ± 0.015 mL100·mL^−1^·min^−1^·s^−1^) ([Figure 1c](#f1-copd-1-73){ref-type="fig"}). However, excess flow above baseline measured during the hyperemic period was not significantly different between the groups (COPD 8.3 ± 2.0 mL·100 mL^−1^, control 7.5 ± 3.0 mL·100 mL^−1^; p=0.53).

In the control group, V̇O~2peak~ (L·min^−1^) was significantly correlated with both peak CBF ([Figure 3c](#f3-copd-1-73){ref-type="fig"}) and peak conductance ([Figure 3d](#f3-copd-1-73){ref-type="fig"}), whereas there was no significant relationship between V̇O~2peak~ and peak CBF or peak conductance observed in the COPD group ([Figure 3a, 3b](#f3-copd-1-73){ref-type="fig"}). Peak CBF was not significantly correlated with V̇~Epeak~ or peak heart rate in either group.

Discussion
==========

This is the first study to examine the relationship between peak CBF responses and V̇O~2peak~ in patients with moderate COPD. Although COPD patients had a much lower V̇O~2peak~ than age-matched healthy controls, there was no difference between the groups in resting or peak CBF and conductance. Moreover, the significant positive correlation between either peak CBF or peak conductance and V̇O~2peak~ observed in the healthy older subjects was not seen in the COPD group.

V̇O~2peak~ and the peak power achieved during incremental cycling were markedly lower in the COPD group than in healthy controls. Seven of the subjects in the COPD group stopped exercise because of leg fatigue or a combination of leg fatigue and breathlessness, whereas only two subjects stopped because of shortness of breath alone. Moreover, both groups reached a similar V̇~Epeak~ as a percentage of MVV (84.1% for the COPD group versus 85.9% for the control group) during incremental cycling. Since peak exercise heart rate was significantly lower in COPD patients (79.8% of age-predicted maximum) than in healthy control subjects (100.5% of age-predicted maximum), we conclude that the patients in the present study did not experience a central cardiovascular limitation to exercise. Rather, lower limb muscle fatigue and dyspnea were the primary reasons for stopping exercise.

The only other study to examine CBF responses in COPD patients with strain-gauge plethysmography reported that subjects with mild-to-severe COPD had significantly greater resting CBF, but similar peak CBF when compared with control subjects ([@b5-copd-1-73]). When the COPD group was further differentiated into those with mild obstruction (FEV~1~ 78.9 ± 5.6% predicted) and those with more severe obstruction (FEV~1~ 49.2 ± 17.6% predicted), it was revealed that only those with severe disease had significantly higher resting CBF than healthy control subjects. While the authors concluded that patients with COPD tended to be chronically vasodilated when compared with healthy controls, their results suggest that this statement applies only to subjects with more severe obstruction. The resting CBF results of the present study disagree with those of [@b5-copd-1-73]. We found that in a group of COPD patients with a comparable degree of expiratory flow limitation (FEV~1~ 52.2 ± 7.6% predicted) to the subjects examined in their study, resting CBF was not significantly different from that of healthy control subjects.

In the present study, we hypothesized that peak CBF would be lower in the COPD group than in the control group. However, our results suggest that the ability to maximally vasodilate the calf muscle vasculature has not been lost in individuals with moderate COPD. The hyperemia that follows ischemia (induced by arterial occlusion) is thought to arise from a combination of myogenic relaxation of blood vessels and the accumulation of locally released vasoactive metabolites (eg, prostaglandins, nitric oxide, K^+^, and H^+^) during the ischemic period ([@b29-copd-1-73]). Evidence suggests that the loss of myogenic tone and hypoxia-induced vasodilator-prostaglandin synthesis contribute primarily to the peak flow response ([@b3-copd-1-73]; [@b8-copd-1-73]; [@b37-copd-1-73]). Additionally, prostaglandins, nitric oxide, and possibly other vasoactive metabolites such as adenosine mediate the remainder of the hyperemia response ([@b3-copd-1-73]; [@b33-copd-1-73]), as blood flow progressively returns to baseline. Since resting and peak CBF were not different between COPD patients and healthy control subjects, our results suggest that the factors mediating the hyperemic response observed in the present study are not affected by moderate lung disease.

Another factor that has been shown to affect the reactive hyperemic response is muscle mass. [@b34-copd-1-73] demonstrated that sex differences in forearm peak reactive hyperemic flow and excess flow could be accounted for primarily by differences in lean muscle mass between male and female subjects. Therefore, changes in vasodilatory capacity may occur only in more severe COPD, when cachexia is evident. In the present study, percentage body fat, calf volume, and skinfold thickness of the calf muscle were not significantly different between COPD and healthy control groups. This suggests that lean muscle mass of the calf was not different between the two groups and could partly explain the similar blood flow results obtained in this study.

The observation that peak CBF and conductance were significantly correlated with V̇O~2peak~ in healthy control subjects, but not COPD patients, suggests that factors other than vasodilatory capacity limit exercise capacity in patients with COPD. However, this finding does not negate the possibility that impaired blood flow or O~2~ delivery contribute to skeletal muscle fatigue and exercise cessation in COPD patients. Abnormal ventilatory mechanics and dynamic lung hyperinflation in COPD patients could increase the O~2~ cost of breathing during exercise, resulting in the redirection of blood flow from the active limb muscles to the respiratory muscles. The O~2~ cost of breathing is known to be greater for a given ventilatory demand in COPD patients than in healthy controls ([@b16-copd-1-73]). Moreover, a plateau in lower limb blood flow has been reported in some patients with severe COPD during incremental exercise ([@b31-copd-1-73]). This finding suggests a respiratory "steal" of blood that may otherwise have been directed to the exercising muscles, and has also been observed in healthy athletes during intense exercise ([@b10-copd-1-73]). A reduction in muscle perfusion relative to metabolic demand may also occur as a result of a blunted cardiac output response to exercise, which has been reported in some COPD patients during incremental cycling ([@b2-copd-1-73]). Finally, reduced arterial O~2~ content (hypoxemia) as a result of diffusion impairment or ventilation to perfusion inequalities in patients with COPD may adversely affect O~2~ diffusion across the capillary--muscle interface during periods of high metabolic demand. Studies have shown that O~2~ supplementation in COPD patients with varying degrees of hypoxemia enhances O~2~ delivery and muscle blood flow and increases V̇O~2~ and peak power output ([@b28-copd-1-73]; [@b19-copd-1-73]).

While we found no difference between the groups in peak CBF, the rate of decline in CBF (ie, duration of hyperemic flow) following ischemia was significantly slower in COPD patients than in control subjects ([Figure 1c](#f1-copd-1-73){ref-type="fig"}). The magnitude of the hyperemic response (total excess flow) is dependent on peak flow when the period of ischemia is 5 minutes or less; when ischemia is imposed for longer periods, total excess flow is primarily affected by a longer duration of hyperemia, or a slower rate of decay in blood flow is observed ([@b24-copd-1-73]; [@b3-copd-1-73]; [@b34-copd-1-73]). Thus, it is not clear what the slower rate of decay in peak CBF in COPD patients reflects, considering that the duration of ischemia in the present study was 5 minutes and excess flow values were similar for both groups.

One could hypothesize that the slower fall in CBF (and calf conductance) reflects a slower "washout" of metabolites following the period of ischemia or a greater accumulation of vasoactive metabolites during the ischemic period. [@b8-copd-1-73] hypothesized that the decay in blood flow following ischemia could be determined by the interaction between vasodilating and vasoconstricting prostaglandins. In COPD patients, urinary levels of prostaglandin-like compounds such as isoprostane F2α-III, a marker of oxidative stress, are greater than in healthy control subjects ([@b26-copd-1-73]). These compounds could interact with locally produced prostaglandins during as well as after ischemia to affect the rate of blood flow decay. The selective loss of slow-twitch oxidative fibers ([@b36-copd-1-73]) and decreased activity of oxidative enzymes ([@b18-copd-1-73]) in the skeletal muscles of COPD patients could also result in a greater and/or more prolonged efflux of vasoactive metabolites (K^+^ and H^+^) into the circulation during the ischemic period. Alternatively, the difference in the rate of decay between the two groups may not be physiologically important despite attaining statistical significance, since similar excess flow values were obtained for both groups.

In summary, we tested the hypothesis that a reduced vasodilatory capacity would contribute to the diminished exercise capacity observed in COPD patients. Contrary to our hypothesis, we demonstrated that there were no differences in either baseline or peak CBF between patients with COPD and a group of age-matched, healthy controls. Moreover, peak CBF and conductance were significantly correlated with V̇O~2peak~ in the control subjects but not in the COPD patients. The results of this study show that vasodilatory capacity is not related to a loss of exercise capacity in patients with moderate COPD. Future studies should examine the effect of manipulating the duration of ischemia on total excess flow and the rate of blood flow decay, as well as the effect of disease severity and exercise training on reactive and functional hyperemia in COPD patients.

This project was supported by the Breathlessness Research Charitable Trust, United Kingdom.

![(a) Plethysmograph tracing in a representative subject illustrating the hyperemic blood flow response following 5 minutes of arterial occlusion. The vertical dotted line (time 0 s) indicates the point when the cuff was released after 5 minutes of ischemia, with the first blood flow measurement performed 7 seconds after cuff release. The figure inset shows the slope of the initial increase in calf volume during a single venous occlusion cycle, from which calf blood flow is calculated. (b) Time course change in calf blood flow (CBF) immediately after arterial occlusion in healthy control subjects (open circles) and patients with COPD (filled circles). (c) Log-transformation of the blood flow versus time values presented in panel b. The slopes of the lines of best fit represent the rates of decay in CBF. Only the first 90 seconds of data (ie, the period when CBF was decreasing in both groups) was included in this analysis. The data in panels b and c represent mean values ± SD.](copd-1-73f1){#f1-copd-1-73}

![Baseline and peak calf blood flow (CBF) (a) and conductance (b) responses in healthy control subjects (open bars) and patients with COPD (filled bars). The data represent mean values ± SD.](copd-1-73f2){#f2-copd-1-73}

![Relationship between peak O~2~ uptake and peak calf blood flow, and peak O~2~ uptake and peak conductance in patients with COPD (a, b) and in healthy control subjects (c, d).](copd-1-73f3){#f3-copd-1-73}

###### 

Physical characteristics of the subjects (group means ± SD)

                              Control group   COPD group
  --------------------------- --------------- -------------
  Age (y)                     71.7 ± 3.0      70.1 ± 6.1
  Height (cm)                 172.7 ± 4.8     170.4 ± 5.0
  Body mass (kg)              80.9 ± 9.5      77.8 ± 8.3
  Resting SBP (mmHg)          127.8 ± 13.9    128.0 ± 9.5
  Resting DBP (mmHg)          75.6 ± 5.8      77.4 ± 6.3
  Body fat (%)                21.4 ± 2.8      22.5 ± 4.1
  Sum of leg skinfolds (mm)   22.4 ± 8.2      24.4 ± 8.8
  Calf volume (L)             2.25 ± 0.34     2.18 ± 0.28

**Abbreviations:** DBP, diastolic blood pressure (supine); SBP, systolic blood pressure (supine).

###### 

Pulmonary function test results (group means ± SD)

                                 Control group   COPD group
  ------------------------------ --------------- -------------------------------------------------------
  FVC (L)                        4.08 ± 0.67     3.45 ± 0.61[a](#tfn2-copd-1-73){ref-type="table-fn"}
  FVC (% predicted)              111.0 ± 12.7    96.1 ± 13.4[a](#tfn2-copd-1-73){ref-type="table-fn"}
  FEV~1~ (L)                     3.05 ± 0.59     1.48 ± 0.29[b](#tfn3-copd-1-73){ref-type="table-fn"}
  FEV~1~ (% predicted)           106.0 ± 20.3    52.2 ± 7.6[b](#tfn3-copd-1-73){ref-type="table-fn"}
  FEV~1~/FVC (%)                 74.8 ± 7.1      43.4 ± 7.3[b](#tfn3-copd-1-73){ref-type="table-fn"}
  FEV~1~/FVC (% predicted)       94.3 ± 8.8      54.4 ± 8.9[b](#tfn3-copd-1-73){ref-type="table-fn"}
  MVV (L·min^−1^)                106.7 ± 20.7    52.0 ± 10.0[b](#tfn3-copd-1-73){ref-type="table-fn"}
  RV (L)                         3.33 ± 0.59     4.06 ± 0.69[a](#tfn2-copd-1-73){ref-type="table-fn"}
  RV (% predicted)               135.1 ± 22.9    171.7 ± 26.7[a](#tfn2-copd-1-73){ref-type="table-fn"}
  DL~CO~ (mL·min^−1^·mmHg^−1^)   21.0 ± 3.6      12.4 ± 5.8[b](#tfn3-copd-1-73){ref-type="table-fn"}
  DL~CO~ (% predicted)           86.9 ± 14.9     50.6 ± 22.9[b](#tfn3-copd-1-73){ref-type="table-fn"}

p\<0.05 vs control group.

p\<0.001 vs control group.

**Abbreviations:** DL~CO~, diffusion capacity for carbon monoxide; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity; MVV, maximal voluntary ventilation; RV, residual volume.

###### 

Peak exercise values obtained during incremental cycling (group means ± SD)

                                   Control group   COPD group
  -------------------------------- --------------- ------------------------------------------------------
  V̇O~2peak~ (L·min^−1^)            2.04 ± 0.35     1.19 ± 0.24[a](#tfn5-copd-1-73){ref-type="table-fn"}
  V̇ O~2peak~ (mL·kg^−1^·min^−1^)   25.2 ± 2.6      15.8 ± 3.5[a](#tfn5-copd-1-73){ref-type="table-fn"}
  HR~peak~ (beats·min^−1^)         147 ± 16        118 ± 22[b](#tfn6-copd-1-73){ref-type="table-fn"}
  HR~peak~ (% predicted)           100.5 ± 9.6     79.8 ± 12.3[b](#tfn6-copd-1-73){ref-type="table-fn"}
  V̇ ~Epeak~ (L·min^−1^)            90.7 ± 18.7     42.8 ± 11.3[a](#tfn5-copd-1-73){ref-type="table-fn"}
  Peak RER value                   1.28 ± 0.07     1.06 ± 0.12[a](#tfn5-copd-1-73){ref-type="table-fn"}
  Peak power (W)                   166 ± 27        71 ± 23[a](#tfn5-copd-1-73){ref-type="table-fn"}

p\<0.0001 vs control group.

p\<0.01 vs control group.

**Abbreviations:** HR~peak~, peak exercise heart rate; RER, respiratory exchange ratio; V̇~Epeak~, peak minute ventilation;V̇O~2peak~, peak O~2~ uptake.
